Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Naproxen
Stirling Anglian Pharmaceuticals Ltd
M01AE02
Naproxen
250mg
Effervescent tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 10010100; GTIN: 5060384790244
Package leaflet: Information for the patient STIRLESCENT 250 MG EFFERVESCENT TABLETS NAPROXEN Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if their symptoms are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1 What Stirlescent 250 mg Effervescent Tablets is and what it is used for 2 What you need to know before you take Stirlescent 250 mg Effervescent Tablets 3 How to take Stirlescent 250 mg Effervescent Tablets 4 Possible side effects 5 How to store Stirlescent 250 mg Effervescent Tablets 6 Contents of the pack and other information 1 WHAT STIRLESCENT 250 MG EFFERVESCENT TABLETS IS AND WHAT IT IS USED FOR Stirlescent 250 mg Effervescent Tablets contains the drug naproxen. This is a ‘Non Steroidal Anti Inflammatory Drug’ or NSAID. Stirlescent 250 mg Effervescent Tablets can lessen pain and inflammation (swelling, redness and heat) and is used to treat adults for: • Pain in your muscles, joints and tendons, like strains, gout, arthritis and ankylosing spondylitis. • Period pain. 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE STIRLESCENT 250 MG EFFERVESCENT TABLETS Do not take Stirlescent 250 mg Effervescent Tablets • If you are allergic to naproxen or any of the other ingredients of this medicine (listed in section 6). • If you are allergic to aspirin, other NSAIDs or any other pain relief medicines (such as ibuprofen or diclofenac). • If you have a peptic ulcer (ulcer in your stomach or duodenum) or bleeding in your stomach, or have had two or more episodes of peptic ulcers, stomach bleeding or perforation. • If you have previously experienced bleeding or perforation in y Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Stirlescent 250 mg Effervescent Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 250 mg Naproxen. Excipients with known effect Each effervescent tablet contains: - 0.52 mg benzyl alcohol - 342.01 mg sodium - 0.097 mg sorbitol (E420) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Effervescent tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Stirlescent is used in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Use of the lowest effective dose for the shortest duration necessary to control symptoms is recommended, in order to minimise undesirable effects (see section 4.4). Rheumatoid arthritis, osteoarthritis and ankylosing spondylitis Start at 250 mg, twice daily. Adjust to 500 mg to 1000 mg daily in two divided doses. Acute gout Start at 750 mg, followed by 250 mg every 8 hours. Acute musculoskeletal disorders and dysmenorrhoea Start at 500 mg, followed by 250 mg every 6 to 8 hours. Paediatric population Stirlescent should not be used in the paediatric population because the correct dose cannot be administered using this formulation. Elderly Reduced elimination in the elderly (see section 4.4). Increased risk of serious consequences of adverse reactions. If NSAID use is considered necessary, the lowest effective dose should be used for the shortest possible duration. Monitor regularly for GI bleeding during treatment. Review treatment at regular intervals and discontinue if no benefit is seen, or if intolerance occurs. Renal/hepatic impairment Consider a lower dose in patients with renal or hepatic impairment. Contraindicated in patients with baseline creatinine clearance less than 30 ml/minute due to potential accumulation of naproxen metabolites (see section 4.3). Method of administration Oral. Doses of 1 to 2 tablets must be dissolved Read the complete document